GlassScriptPhysician profile
Jason P Gregorio
NPI 1467643643
$238,425.20
in general payments reported to CMS, 2019-2025
11 companies · $33K in 2025
The $33K reported for 2025 was more than what 98% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $34K · 2021: $35K · 2022: $37K · 2023: $37K · 2024: $31K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $101K · Food and Beverage: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $101,090.12 |
| Food and Beverage | $144.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $137,084.80 | 2019-2024 | Hizentra, Haegarda |
| Csl Plasma INC. | $101,090.12 | 2023-2025 | |
| Kaleo, INC. | $68.12 | 2022-2023 | Auvi-Q |
| Astrazeneca Pharmaceuticals LP | $47.99 | 2022 | |
| Incyte Corporation | $33.28 | 2022 | |
| Amgen INC. | $21.31 | 2023 | Tezspire |
| Optinose US, INC. | $20.22 | 2022 | |
| Blueprint Medicines Corporation | $16.73 | 2023 | Ayvakit |
| Bio Products Laboratory USA, INC. | $15.91 | 2022 | |
| Biocryst US Sales Co., LLC | $14.94 | 2022 | |
| Redhill Biopharma INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Gregorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.